Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study

Stephen K. Williamson; John Crowley; Robert B. Livingston; Geoffrey Weiss

doi:10.1007/BF00873917

Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study

Stephen K. Williamson, John Crowley, Robert B. Livingston, Geoffrey Weiss

Research output: Contribution to journal › Article › peer-review

3 Scopus citations

Abstract

Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m²/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.

Original language	English (US)
Pages (from-to)	81-83
Number of pages	3
Journal	Investigational New Drugs
Volume	11
Issue number	1
DOIs	https://doi.org/10.1007/BF00873917
State	Published - Feb 1993
Externally published	Yes

Keywords

6-thioguanine
chemotherapy
phase II
small cell lung cancer

ASJC Scopus subject areas

Oncology
Pharmacology
Pharmacology (medical)

Access to Document

10.1007/BF00873917

Cite this

@article{128ea69858084a5e9299ef5171637acc,

title = "Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study",

abstract = "Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.",

keywords = "6-thioguanine, chemotherapy, phase II, small cell lung cancer",

author = "Williamson, {Stephen K.} and John Crowley and Livingston, {Robert B.} and Geoffrey Weiss",

year = "1993",

month = feb,

doi = "10.1007/BF00873917",

language = "English (US)",

volume = "11",

pages = "81--83",

journal = "Investigational New Drugs",

issn = "0167-6997",

publisher = "Springer",

number = "1",

}

TY - JOUR

T1 - Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study

AU - Williamson, Stephen K.

AU - Crowley, John

AU - Livingston, Robert B.

AU - Weiss, Geoffrey

PY - 1993/2

Y1 - 1993/2

N2 - Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.

AB - Nineteen eligible patients with recurrent small cell lung cancer were treated with a 120 hour continuous infusion of 6-thioquanine at a starting dose of 35 mg/m2/day. There were no responses in these 19 patients. Toxicity was acceptable with the primary toxicity being hematologic. Based on this trial, 6-thioquanine is not felt to have significant antitumor activity in this patient population.

KW - 6-thioguanine

KW - chemotherapy

KW - phase II

KW - small cell lung cancer

UR - http://www.scopus.com/inward/record.url?scp=0027300489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027300489&partnerID=8YFLogxK

U2 - 10.1007/BF00873917

DO - 10.1007/BF00873917

M3 - Article

C2 - 8394296

AN - SCOPUS:0027300489

SN - 0167-6997

VL - 11

SP - 81

EP - 83

JO - Investigational New Drugs

JF - Investigational New Drugs

IS - 1

ER -

Phase II trial of 6-thioguanine administered as 120 hour continuous infusion for refractory or recurrent small cell lung cancer - A Southwest Oncology Group study

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this